.beta.-l-2'-deoxynucleosides for the treatment of resistant hbv strains and combination therapies
CA 2498731 C · Owner: Patty, April L. · Inventors: Standring, David; Patty, April L.; Seifer, Maria
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
It has been discovered that .szlig.-L-2'-deoxynucleosides are active against drug~resistant hepatitis B virus with mutations. A method for treating lamivudine resistant HBV (M552V) in a host is provided that includes administering a .szlig.-L-2'~deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. In addition a method for preventing , lamivudine resistant HBV (M552V) mutation from occurring in a naïve host is provided that includes administering a .szlig.-L-2'-deoxynucleoside or its pharmaceutically acceptable salt, ester or prodrug. A method for preventing and/or suppressing the emergence of the HBV double mutant (L528M/M552V) in a host is also provided that …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 15, 2003 and granted October 30, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 15, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 15, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.